modelTiomolibdicAcid
Extends from Pharmacolibrary.Drugs.ATC.A.A16AX22.
Information
| name: | TiomolibdicAcid | |
| ATC code: | A16AX22 | route: | oral |
| compartments: | 1 | |
| dosage: | 300 | mg |
| volume of distribution: | 50 | L |
| clearance: | 5 | L/h |
| other parameters in model implementation | ||
Tiomolibdic acid, also known as bis-choline tetrathiomolybdate, is a chelating agent mainly investigated for the treatment of Wilson's disease, a rare genetic disorder of copper metabolism. It acts by binding copper and preventing its toxic accumulation. It is not approved in all countries for clinical use but has received orphan drug designation and has been approved in the EU under the name Cufence.
Pharmacokinetics
No published clinical pharmacokinetic studies reporting specific parameters for tiomolibdic acid (bis-choline tetrathiomolybdate) in humans were identified. The following parameters are estimated based on typical values for chelating agents administered orally.
References
Forrest, JA, et al., & Prescott, LF (1982). Clinical pharmacokinetics of paracetamol. Clinical pharmacokinetics 7(2) 93–107. DOI:10.2165/00003088-198207020-00001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/7039926
Keizer, RJ, et al., & Beijnen, JH (2010). Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clinical pharmacokinetics 49(8) 493–507. DOI:10.2165/11531280-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20608753
Echizen, H (2016). The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. Clinical pharmacokinetics 55(4) 409–418. DOI:10.1007/s40262-015-0326-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26369775
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)